Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of TS-172 plus phosphate binders in hyperphosphatemia on hemodialysis
jRCT2031240568Phase 2Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hyperphosphatemia and chronic kidney disease (CKD) comparing TS-172 + phosphate binders with Placebo + phosphate binders (2 arms). Primary endpoint: Achievement rate of target serum phosphorus level at Week 8. Started Jan 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031240568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240568.